TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Epstein Barr virus-positive lymphoma, including the following subtypes:~  * Post-transplantation lymphoma~ * Burkitt's lymphoma~ * Hodgkin's lymphoma~ * T-/NK-cell lymphoma~* Unresponsive to, or relapsed after, at least 1 prior chemotherapy regimen~* Bidimensionally measurable disease by CT scan~* At least 1 lesion ≥ 1.5 cm in the greatest diameter~* Age 18 and over~* ECOG 0-2 OR~* Karnofsky 50-100%~* Life expectancy More than 3 months~* Hematopoietic~  * Absolute neutrophil count ≥ 1,000/mm\^3 (no growth factor support within the past 4 weeks)~ * Hemoglobin ≥ 9.0 g/dL~ * Platelet count ≥ 50,000/mm\^3 (no platelet transfusions within the past 4 weeks)~* Hepatic~  * Bilirubin ≤ 2.0 times upper limit of normal (ULN)~ * AST and ALT ≤ 2.5 times ULN (5 times ULN in patients with liver involvement)~ * No active hepatitis B or C~* Renal~  * Creatinine clearance ≥ 60 mL/min~ * Sodium \> 130 mmol/L~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* At least 4 weeks since prior immunotherapy~* At least 4 weeks since prior chemotherapy~* At least 4 weeks since prior radiotherapy~* More than 4 weeks since prior major surgery unless fully recovered~* Recovered from all prior therapy~* At least 4 weeks since prior investigational agents~Exclusion Criteria:~* primary or secondary CNS lymphoma or HIV-related lymphoma~* known brain metastases~* myocardial infarction within the past 6 months~* acute ischemia or new conduction system abnormalities by electrocardiogram~* symptomatic congestive heart failure~* unstable angina pectoris~* cardiac arrhythmia~* hospitalized~* pregnant or nursing~* other uncontrolled illness~* ongoing or active systemic infection~* psychiatric illness or social situation that would preclude study compliance~* history of allergic reaction attributable to compounds of similar chemical or biological composition to study drugs~* sensitivity to boron, mannitol, bortezomib, or ganciclovir~* concurrent corticosteroids (≥ 10 mg of prednisone or equivalent)~* concurrent radiotherapy~* other concurrent anticancer therapy~* other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib + ganciclovir (Type: EXPERIMENTAL): Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Supplementation in the Elderly With Weight Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 65 and older~* Non-smokers~* Weight loss \>3% body weight over 6-12 months~* BMI ≤ 25~* Living independently or in an assisted living facility~Exclusion Criteria:~* Medical conditions that would lead to weight loss~  * Active cancer undergoing treatment (chemotherapy, radiation therapy, or planned surgical intervention)~ * CKD stage IV-V (eGFR \<30) based on medical records within the last 12 months~ * Presence of dysphagia or odynophagia~ * Actively taking blood thinner such as Warfarin~ * Known history of cirrhosis with presence of ascites~ * History of a surgical procedure for weight loss (e.g. gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, lap-band)~ * Any abnormal lab findings outside of normal limits as determined by the investigator~* Dietary conditions~  * Diet restrictions including vegetarianism, veganism, soy-free diet,~ * Fish and/or fish oil allergy or intolerance~ * Milk allergy excluding lactose intolerance~ * Follows a kosher diet~* Medications~  * Use of appetite stimulants (including megestrol, dronabinol and cyproheptadine).~ * Does not include medications used for depression (e.g. mirtazapine, paxil) if patient has been on a stable dose of this medication for at least 3 months prior to the start of this study~ * If participant is already taking a fish oil supplement, he/she must be willing to either stop the supplement or take the supplement the investigators are using in the study depending on the randomization assignment~* Additional~  * Patient has implantable device such as a pacemaker or ICD~ * Unable to complete 6-minute walk test at baseline~ * Hospitalization within the last 30 days~ * Participation in a therapeutic research study within 30 days of baseline~ * Living in a skilled nursing facility or long-term care facility~ * Any other medical condition that principal investigator or co-investigators deem would preclude the patient from study participation

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Supplement + Fish Oil (Type: EXPERIMENTAL): Participants will mix 5 scoops of powdered nutrition supplement with 8 oz of cold water (2x/day). The supplemental shake will be consumed on two separate occasions daily. Omega-3 fish oil supplement is in capsule form for intake once daily.~The NutraWell nutrition powder and OmegaRich fish oil supplement will be provided by and distributed from DoWell Laboratories (Irvine, CA - USA).
- Control (Type: NO_INTERVENTION): No dietary supplements. Participants will continue current intake.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treating Acute Pancreatitis With Dabigatran, a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute Pancreatitis (presence at least two of three features: typical pain, amylase or lipase \>3 times UNL and AP on images)~* 18-75 years old~* Willingness to sign the informed consent~* Symptom onset within 72 hours~Exclusion Criteria:~* Under 18 years of age or over 75 years of age~* Pregnancy or lactating~* Presence of pseudo aneurysm on CT~* Predicted severe acute pancreatitis~* Unwilling or unable to sign the informed consent~* Had recent surgery or sphincterotomy~* Active pathological bleeding~* Concurrent use of anti-coagulation~* Known serious hypersensitivity reaction to Dabigatran~* CrCI \<30mL/min or on dialysis~* Mechanical prosthetic valves~* Liver disease~* Cancer~* On Chemotherapy or immunosuppressant~* Persistent ALT, AST, Akl Phos \>2 x ULN~* Active hepatitis C, active hepatitis B, and active hepatitis A~* Anemia (hemoglobin \<10g/dL)~* Thrombocytopenia~* Concomitant use of P-gp inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dabigatran Etexilate Mesylate (Type: ACTIVE_COMPARATOR): Dabigatran 150mg BID for 3 days
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard treatment for acute pancreatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of High Order Aberrations in Late Stages Keratoconus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* to be able to understand an information and give a consent~* patients over 18~* patients with keratoconus~* affiliated to medical insurance.~Exclusion Criteria:~* non keratoconus patients~* patients under 18~* pregnant women or nursing mothers~* ocular surgery 90 days before inclusion~* ocular infection~* keratitis~* restless patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Measurement of aberrations in patients with keratoconus of grade 1
- Group 2 (Type: ACTIVE_COMPARATOR): patients with keratoconus of grade 2
- Group 3 (Type: EXPERIMENTAL): patients with keratoconus of grade 3
- Group 4 (Type: EXPERIMENTAL): patients with keratoconus of grade 4

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Amylose Maize Starch for Treatment of Cholera

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~A participant is considered eligible for participation in the trial if the following inclusion criteria are satisfied on admission (Day 1, before randomization) to the hospital:~1. Participant is a male between 18 and 65 years of age inclusive~2. Severe watery diarrhea without fecal blood of less than 48 hours (with passage of 3 or more watery stools in the 24 hours before admission)~3. Signs of severe dehydration as per ICDDR,B guidelines (modified WHO guideline)~4. Dipstick test/Dark-field examination positive for Vibrio cholera~5. Written informed consent is provided~6. Participant is willing and able to comply with all trial requirements~EXCLUSION CRITERIA:~A participant who meets any of the following criteria on admission (before randomization) to the hospital will not qualify for the study~1. Evidence or history of any clinically significant illness as per the Investigator's discretion.~2. Known case of HIV or Hepatitis B~3. History of cancer~4. Known renal disease~5. Frequent excessive alcohol use, binge drinking (e.g. men consume 5 or more drinks in about 2 hours) or use of illicit drugs within the past two years~6. History of receiving antimicrobial or anti-diarrheal medication (loperamide, diphenoxylate, etc.) within seven days of admission~7. Concomitant infection requiring antimicrobial therapy~8. Donated blood or plasma or experienced clinically significant loss of blood within eight weeks prior to admission or who plan to donate blood within 1 month after study participation~9. Clinically significant abnormal laboratory test results as determined by the investigator~10. Treatment within 30 days prior to admission (or five half-lives of the compound, if longer) with any investigational agent or device~11. History of seizure (including febrile seizure) or loss of consciousness;~12. History of any GI Surgery related to Bowel resections and gastric anastomoses in past except Appendicitis~13. For any reason, deemed by the investigator to be inappropriate for this study, including participants who are unable to communicate or to cooperate with the investigator or designee~14. Prior enrolment in this trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Males (Type: None): Adult 18-65

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects ages 4-85~* Subjects that are diagnosed with Glycogen Storage Disease Type Ib (GSD1b, von Gierke disease)~* Subjects who are G339C Homozygous or L348FS Homozygous or G339C/ L348FS heterozygous or are the biological parent of subjects diagnosed with Glycogen Storage Disease Type Ib (GSD1b, von Gierke disease) and are a biological parent of a subject in Cohort 1 (G339C homozygous) or Cohort 2 (L348FS homozygous)~* Subjects or guardians must be willing and able to provide appropriate photo identification to mobile phlebotomist during at-home visit for verification of identity~* Subjects and/or Guardians must be willing and able to provide appropriate written informed consent and/or assent, as applicable~Exclusion Criteria:~* Subjects will be excluded if they experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the last two months. For subjects in the pediatric population, subjects will be excluded if they experienced excess blood loss, including blood donation defined as 3 mL/kg or up to 50 mL in the last 8-weeks.~* For requests that do not include pregnant subjects, subjects will be excluded if they are pregnant or nursing.~* For requests that do not include subjects with infectious diseases, subjects will be excluded if they have current, active HIV, hepatitis or other infectious diseases (self-reported or medical history reviewed).~* Subjects will be excluded if they have taken an investigational product in the last 30 days.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Study Arms:
- GSD1b G339C Homozygous (n=3) (Type: None): None
- GSD1b L348FS Homozygous (n=3) (Type: None): None
- GSD1b G339C/ L348FS Heterozygous (n=3) (Type: None): None
- GSD1b Parents (n=6) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~children with acute generalized seizures, continuing for a minimum of 5 minutes, who have not received any anti-convulsant therapy within 1 hour of presentation.~Exclusion Criteria:~Children who have received anticonvulsant treatment within 1 hour prior to assessment. Any child whose seizures cease following correction of hypoglycaemia. Children with a known adverse reaction to lorazepam.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Do Home Monitors Improve Blood Pressure Control?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* over 18 years old,~* diabetes as defined by HgA1C over 6.5%,~* uncontrolled blood pressure (SBP \> 130 and or DBP \> 80)~Exclusion Criteria:~* pregnancy,~* transplanted organ,~* MI/CHF/CVA within 3 months,~* dialysis,~* arrhythmia,~* metastatic cancer,~* dementia,~* visual or hearing difficulties

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): This group will not get a home blood pressure monitor.
- Home monitors (Type: EXPERIMENTAL): This group will be given a home blood pressure monitor to use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Essential Tremor in Children and Adolescent

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject whose age is between 3 and 18 years~* Subject affiliated to a social security scheme~* Parents or subjects who have been informed of the course and consequences of the study by an investigator and who have signed the informed consent form for prospective inclusion or who have given their non-opposition for retrospective inclusion.~* Diagnosis of essential tremor established according to the diagnostic criteria of the Movement Disorders Society (1998), by a neuropediatrician or a neurologist, specialist in abnormal movements. The diagnosis is based on the presence of the following criteria: bilateral action tremor of the hands and forearms, absence of other neurological signs.~* Availability of an electromyogram for retrospective inclusions.~Exclusion Criteria:~* Abnormal neurological examination outside tremor~* Family history or personal dysthyroidism~* Existence of a global psychomotor or motor developmental delay~* Taking medication that may induce tremor~* known poisoning by heavy metals, bismuth, mercury, methyl bromide~* Severe appearance of the tremor~* Tremor suggestive of a psychogenic origin~* Abnormal or non-existent brain MRI if family case

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- child essential tremor (Type: OTHER): electromyogram with accelerometer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with known or recently diagnosed cirrhosis who~  1. are admitted to the ICU because of persistent hypotension or~ 2. develop persistent hypotension while admitted to the ICU,~secondary to proven or suspected infection, in both cases despite adequate fluid resuscitation and with persistent need for low-dose norepinephrine to maintain a mean arterial blood pressure \> 60 mmHg or \> 65 mmHg if accompanied by signs of hypoperfusion, are eligible for study entry. The diagnosis of cirrhosis is preferably made by histology or based on imaging and laboratory findings.~Exclusion Criteria:~* Age \< 18 or ≥ 80 years~* Patients receiving any vasopressor medication for more than 24 h prior to administration of study drug. Terlipressin initiated for treatment of hepatorenal syndrome or variceal bleeding is allowed~* Patients with known hypoadrenalism~* Active GI bleeding (unless controlled for \>72 hours) or hemorrhagic shock.~* Cardiogenic shock or severe cardiac dysfunction (CI \<2 l/min/ m2)~* Active uncontrolled hepatitis B infection~* HIV infection~* Evidence of current malignancy (except hepatocellular carcinoma within transplant criteria or non-melanocytic skin cancer)~* Therapy with any corticosteroid (oral or intravenous) in the last 3 months~* Patients who received etomidate within the past 3 days~* Severe acute alcoholic hepatitis (biopsy proven)~* Chronic hemodialysis~* Severe chronic heart disease (NYHA class III or IV)~* Severe chronic obstructive pulmonary disease (GOLD III or IV)~* Severe psychiatric disorder~* Child-Pugh score C14 -15~* SOFA score \> 16 points at inclusion~* Pregnant or breastfeeding women~* Contraindications for systemic steroids~* Refusal to consent~* Patients who cannot provide prior informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- group A (Type: ACTIVE_COMPARATOR): Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)
- group B (Type: PLACEBO_COMPARATOR): Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Individual Computer Aided Design/Manufactured (CAD/CAM) - Based Implants Consisting on Hydroxylapatite and Titanium to be Used in Cranioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Skull defects without the possibility to be covered with the missing own bone~2. Size of the defect ≥ 16 cm2~3. Age ≥ 18~4. Written informed consent of the patient~Exclusion Criteria:~1. Active tumor~2. ASA 4 classification~3. Allergic disposition to ceramic or titanium~4. Concomitant participation in other clinical trials~5. Pregnant or nursing women~6. Expected low compliance~7. HIV positive~8. Active drug abuses

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Titanium (Type: ACTIVE_COMPARATOR): Titanium implant for cranioplasty. Titanium implants are used since 10 years in Germany because of their high biocompatibility and accuracy of fit.
- Hydroxylapatite (Type: EXPERIMENTAL): Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues